Dr. Salem on Selecting the Appropriate Treatment Approach in HCC

Video

Riad Salem, MD, discusses considerations for selecting the appropriate treatment approach for patients with hepatocellular carcinoma.

Riad Salem, MD, vice chair for Image Guided Therapy, Department of Radiology, chief of Vascular and Interventional Radiology in the Department of Radiology, and professor of Radiology (Vascular and Interventional Radiology), Medicine (Hematology and Oncology) and Surgery (Organ Transplantation) at the Feinberg School of Medicine, discusses considerations for selecting the appropriate treatment approach for patients with hepatocellular carcinoma.

Lesions that are visible via ultrasound, that are less than 3 cm, or are isolated from critical structures, are well suited to ablative therapy, according to Salem. However, if the lesion is more difficult to identify or is closer to adjacent structures, arterial locoregional therapy or external radiotherapy are recommended, Salem says.

If both options have failed, or the patient is not a candidate for these approaches, systemic therapies can be considered. Agents such as lenvatinib (Lenvima) are generating excitement in the downstaging setting due to the high response rates observed with its use, according to Salem. Although these agents need to be further studied and understood, these strategies are viable depending on the patient's clinical factors, Salem concludes.

Related Videos
Video 6 - "Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer"
Video 5 - "Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC"
Michael J. Overman, MD
Ilyas Sahin, assistant professor, Medicine, Department of Medicine, Division of Hematology & Oncology, University of Florida College of Medicine
Michael J. Overman, MD
Manish A. Shah, MD, director, Gastrointestinal Oncology Program, Weill Cornell Medicine; chief, Solid Tumor Service, co-director, Center for Advanced Digestive Disease, NewYork Presbyterian
Katrina S. Pedersen, MD, MS
Efrat Dotan, MD
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.